Jakafi® (Ruxolitinib) CML Chronic Myeloid Leukemia
Jakafi® is a selective inhibitor of Janus kinases 1 and 2 (JAK1 and JAK2). Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.
Extract from Incite - Jakafi® (ruxolitinib)
ARTICLES
New Drug (ruxolitinib) Helps Some Bald Patients Regrow Hair
August 17, 2014, The New York Times
Dr. Mesa on Ruxolitinib in Chronic Myeloid Leukemia
May 8, 2013, OncLive
The Mechanism of Action of Ruxolitinib in CML
March 13, 2013, Targeted Oncology
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
May 17, 2012, Journal Blood
New Drug (ruxolitinib) Helps Some Bald Patients Regrow Hair
August 17, 2014, The New York Times
Dr. Mesa on Ruxolitinib in Chronic Myeloid Leukemia
May 8, 2013, OncLive
The Mechanism of Action of Ruxolitinib in CML
March 13, 2013, Targeted Oncology
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
May 17, 2012, Journal Blood
